A leading healthcare management company to improve the business‘s market access strategy as it expands the install base of its signal processing technology for arrhythmia care
Westport, CT, Dec. 21, 2021 /GLOBE NEWSWIRE/ — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and discover the full range of ECG and intracardiac signals, announced today that it has appointed Access Strategy Partners, Inc. to advise on the next phase of commercial deployment.
Led by medical device sales experts, Boston-based Access Strategy Partners brings to BioSig deep expertise in go-to-market, contract management, execution and value proposition optimization. The company’s co-founder and president, Jim Walker, is a senior healthcare executive with more than 30 years of experience in sales, marketing, sales operations and national account management at some of the leading companies. in the medical device industry, including Boston Scientific Corporation. (BSC) and Johnson & Johnson. His experience spans national and international responsibilities, focusing on strategic market development and key customer management. During his 18-year career with Boston Scientific Corporation, Mr. Walker established the organization as a recognized leader among group purchasing organizations. He built a world-class enterprise sales organization that represented the entire BSC portfolio for supply chain executives at all levels of market aggregation, including Group Purchasing Organizations (GPOs) , national and regional integrated delivery networks (IDNs), and national and regional purchasing alliances. . Mr. Walker was the company’s lead strategic pricing advisor and secured support from the management team to invest in and develop a company-wide contract management system that provides pricing information global and profitability analysis capabilities.
“ASPI was founded to provide strategic relationship management to emerging medical device companies,” said Jim Walker. “Our business conversations are focused on delivering excellent clinical and economic value. BioSig and its breakthrough PURE EP™ product deliver significant benefits to physicians and patients that we are excited to introduce to healthcare providers.”
Under the terms of the new collaboration, Access Strategy Partners will advise BioSig on all aspects of business strategy, including economic value modeling, hospital administration engagement and contracts.
“Jim and his highly skilled team at Access Strategy Partners bring us proven success strategies to accelerate time to market. Take a close look at ASPI’s track record of helping emerging medical device companies, and you’ll see what we have seen: high revenue growth rates with sustainability. We look forward to learning from some of the brightest minds in medical device sales as we leverage key insights from our initial business efforts to bring our disruptive technology to the level of hospitals nationwide,” commented Kenneth L. Londoner, President and CEO of BioSig Technologies, Inc.
The PURE EP™ is an FDA 510(k) cleared Class II non-invasive device that aims to improve the efficiency and effectiveness of cardiac electrophysiology procedures. To date, over 70 physicians have treated over 1750 patient cases with the PURE EP™ System.
Clinical data acquired by the PURE EP™ System in a multicenter study at the Texas Cardiac Arrhythmia Institute at St. David’s Medical Center, Mayo Clinic Jacksonville, and Massachusetts General Hospital was recently published in the Journal of Cardiovascular Electrophysiology and is available electronically in open access via the Wiley Online Library. Study results showed a 93% consensus among blinded reviewers with an overall 75% improvement in intracardiac signal quality and confidence in interpreting PURE EP™ signals compared to conventional sources.
The company recently appointed a former Abbott senior sales manager, Mr. Gray Fleming, as chief commercial officer. BioSig is undergoing a targeted commercial launch of the PURE EP™ System in the Northeast, Texas and Florida and is routinely used in some of the nation’s leading Centers of Excellence, including the Mayo Clinic in Rochester, MN , and St. David’s Medical Center in Austin, TX.
About BioSig Technologies
BioSig Technologies is a medical technology company that markets a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intracardiac signals (www.biosig.com).
The Company’s first product, PURE EP™ System, is a computer-based system for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing electrocardiographic and intracardiac signals for patients undergoing electrophysiology procedures ( EP) in an EP laboratory.
This press release contains “forward-looking statements”. Such statements may be preceded by the words “intends”, “may”, “will”, “plans”, “expects”, “anticipates”, “projects”, “predicts”, “estimates”. , “aim”, “believe”. ,” “hopes”, “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the control of the Company and cannot be predicted or quantified and, therefore, actual results may differ materially from those expressed or implied by such forward-looking statements.These risks and uncertainties include, but are not limited to, the risks and uncertainties associated with ( (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates at scale by ourselves or in conjunction with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size e and the nature of our competitors; (v) the loss of one or more key executives or scientists; and (vi) difficulties obtaining regulatory approval to commercialize our products and product candidates. More detailed information about the company and the risk factors that may affect the making of forward-looking statements is set forth in the company’s filings with the Securities and Exchange Commission (SEC), including the company’s annual report on Form 10. -K and its Quarterly Report Reports on Form 10-Q. Investors and security holders are urged to read these materials free of charge on the SEC’s website at http://www.sec.gov. The Company undertakes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
BioSig Technologies, Inc.
Vice President, Investor Relations
55 Green Farms Road
Westport, Connecticut 06880